Table 2

Univariate analysis of mortality at 7-days

Crude OR (95% CI)p Value
Age (years)
 <311
 31–502.19 (0.37 to 13.15)0.389
 51–704.89 (1.11 to 21.54)0.036
 >709.71 (2.30 to 40.97)0.002
Gender
 Female1
 Male0.90 (0.58 to 1.42)0.662
Speciality at the time of first episode
 Critical care1
 Medical1.93 (1.14 to 3.27)0.014
 Other0.55 (0.27 to 1.10)0.093
Neutropoenia1.26 (0.52 to 3.02)0.609
Pitt score
 01
 11.92 (0.75 to 4.92)0.175
 21.63 (0.62 to 4.27)0.323
 34.08 (1.58 to 10.56)0.004
 44.01 (1.63 to 9.86)0.002
 5–74.69 (1.94 to 11.35)0.001
 8–922.44 (6.53 to 77.11)<0.001
CCI
 01
 11.77 (0.62 to 5.05)0.285
 22.95 (1.10 to 7.87)0.031
 33.17 (1.18 to 8.55)0.023
 44.50 (1.56 to 13.01)0.005
 52.15 (0.63 to 7.39)0.224
 64.70 (1.58 to 13.98)0.005
 7–95.77 (2.00 to 16.61)0.001
Site of infection
 CVC1
 Catheter-associated UTI4.16 (1.86 to 9.33)0.001
 Non-catheter-associated UTI2.93 (1.20 to 7.14)0.018
 Biliary tract0.78 (0.09 to 6.65)0.821
 Other2.34 (1.17 to 4.70)0.016
Delay in appropriate treatment (days)
 <11
 ≥1 and <21.11 (0.63 to 1.98)0.717
 ≥2 and <30.67 (0.27 to 1.68)0.394
 ≥31.24 (0.40 to 3.81)0.712
Organism susceptibility
 Fully susceptible1
 Partially resistant1.11 (0.67 to 1.81)0.690
 Multiple drug resistance1.54 (0.94 to 2.54)0.090
  • Generalised estimating equations were used to account for dependency between multiple bacteraemic episodes for 84 patients.

  • CCI, Charlson comorbidity index; CVC, central venous catheter; UTI, urinary tract infection.